JMD Properties Inc (SLDX PINK) stock market data APIs
$0.0465
0(0%)
as of July 18, 2025
Try our APIs with
free plan!
JMD Properties Inc Financial Data Overview
Price chart is built with
Anychart
Stella Diagnostics, Inc., a research diagnostics company, engages in developing molecular diagnostics tools and new drug targets for esophageal diseases. It uses targeted mass spectrometry to determine the level of disease progression in tissue of the lower esophagus. The company's technology notifies gastroenterologists, surgical oncologists, and pathologists, which patients are high risk for disease progression into precancer or cancer. The company was formerly known as JMP Properties, Inc. and changed its name to Stella Diagnostics, Inc. in April 2021. Stella Diagnostics, Inc. is headquartered in Salt Lake City, Utah.
Prev. Close
0.0465
Open
0.0465
High
0.0465
Low
0.0465
52 wk Range
0.04-0.08
Market Cap
18 598 K
Shares Outstanding
402 M
EPS
-0.0016
Beta
-7.563
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get JMD Properties Inc data using free add-ons & libraries
Get JMD Properties Inc Fundamental Data
JMD Properties Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
JMD Properties Inc News
New
Stella Diagnostics and Mayo Clinic to Present Data on the Utility of the STLA101 Test for Esophageal Cancer Staging at the 2022 AGA Digestive Disease Week Conference
SALT LAKE CITY, May 11, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and cancer...
Stella Diagnostics Announces Leadership Changes: Dr. Joe Abdo Assumes a New Role as Chief Scientific Officer, and Director David Seaburg is Appointed Chief Executive Officer
SALT LAKE CITY, April 22, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and canc...
Stella Diagnostics Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting
SALT LAKE CITY, April 06, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and canc...
Stella Diagnostics to Present at “Next Big Thing” Session at Society of American Gastroenterologists and Endoscopic Surgeons Annual Meeting
Stella Diagnostics Designated as a Semi-Finalist for SAGES Shark Tank 2022 Stella Diagnostics and Collaborators to Give a Clinical Science Data Presentation at Major Medical Conference in Denver DENV...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
